Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
2023-04-01
This study is the first clinical study in PD-1 resistant patients with head and neck squamous
cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors,
which explores the new combination therapies urgently needed in clinical practice and lays a
foundation for subsequent studies, with important scientific research significance and
clinical value.
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
Completed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
1997-11-01
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with
hematologic cancer and the persistent fever caused by a low white blood cell count. It is not
yet known which regimen of antibiotics is most effective in preventing infection in these
patients.
PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam
with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or
Hodgkin's disease.
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
1969-12-31
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered
intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for
the empiric treatment of neutropenic fever in patients with a hematologic malignancy or
lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
